Date: 25/05/2021
Results of a study evaluating TAK-831 in adults with Friedreich’s ataxia (FA)
The study evaluating the efficacy and safety of oral luvadaxistat, also known as TAK-831, in adults with Friedreich’s ataxia has been published.
Date: Nov 2019
Takeda announce negative results from TAK-831 clinical trial in FA
Ataxia UK were disappointed to hear that Takeda’s clinical trial, testing TAK-831, did not show an improvement in Friedreich’s ataxia (FA) symptoms compared to the placebo control group. Takeda concluded that although TAK-831 was safe and well-tolerated by people with FA, it was not an effective treatment for this condition.
Date: 11/07/2018
New Friedreich’s ataxia trial started in America
We reported previously about the pharmaceutical company Takeda having an interest in ataxia and them developing a drug that targets the cerebellum. It is really encouraging to see that this work has now progressed to the human trial stage, and a trial has started testing the effect of their drug, called Tak-831, in people with Friedreich’s ataxia.
This is a placebo-controlled trial in 65 people with FA for 12 weeks and their main aim is to test the effect on the function of the arms and hands and manual dexterity (using the 9-hole peg test). They will also test a number of other measures.
Ataxia UK has been actively supporting Takeda by providing advice, information on the patient perspective and introductions. We are hoping to hold a meeting of European patient groups soon to assist in the advancement of the programme. You can read more about the trial here.
